History repeating: guidelines to address common problems in psychedelic science

M van Elk, EI Fried - Therapeutic Advances in …, 2023 - journals.sagepub.com
Research in the last decade has expressed considerable optimism about the clinical
potential of psychedelics for the treatment of mental disorders. This optimism is reflected in …

Pharmacotherapies for treatment-resistant depression: how antipsychotics fit in the rapidly evolving therapeutic landscape

MK Jha, SJ Mathew - American Journal of Psychiatry, 2023 - Am Psychiatric Assoc
One in three adults with major depressive disorder (MDD) do not experience clinically
significant improvement after multiple sequential courses of antidepressants and have …

Must psilocybin always “assist psychotherapy”?

GM Goodwin, E Malievskaia… - American Journal of …, 2024 - Am Psychiatric Assoc
Design Open-label Randomized Randomized, double-blind, placebo-controlled
Randomized, double-blind, placebo-controlled Randomized, double-blind, placebo …

Randomized trial of ketamine masked by surgical anesthesia in patients with depression

TR Lii, AE Smith, JR Flohr, RL Okada… - Nature mental …, 2023 - nature.com
Ketamine may have antidepressant properties, but its acute psychoactive effects complicate
successful masking in placebo-controlled trials. Here we present a single-center, parallel …

Psychedelic therapies reconsidered: compounds, clinical indications, and cautious optimism

JM Mitchell, BT Anderson - Neuropsychopharmacology, 2024 - nature.com
The clinical investigation of psychedelic medicines has blossomed over the last 5 years.
Data from a Phase 3 industry trial and a multicenter Phase 2 industry trial, in addition to …

Ketamine in neuropsychiatric disorders: an update

JN Johnston, B Kadriu, C Kraus, ID Henter… - …, 2024 - nature.com
The discovery of ketamine as a rapid-acting antidepressant led to a new era in the
development of neuropsychiatric therapeutics, one characterized by an antidepressant …

Rapid neuroplasticity changes and response to intravenous ketamine: a randomized controlled trial in treatment-resistant depression

J Kopelman, TA Keller, B Panny, A Griffo… - Translational …, 2023 - nature.com
Intravenous ketamine is posited to rapidly reverse depression by rapidly enhancing
neuroplasticity. In human patients, we quantified gray matter microstructural changes on a …

Repeated (S)-ketamine administration ameliorates the spatial working memory impairment in mice with chronic pain: role of the gut microbiota–brain axis

Y Jiang, X Wang, J Chen, Y Zhang, K Hashimoto… - Gut …, 2024 - Taylor & Francis
Chronic pain is commonly linked with diminished working memory. This study explores the
impact of the anesthetic (S)-ketamine on spatial working memory in a chronic constriction …

Choosing Between Ketamine and Electroconvulsive Therapy for Outpatients With Treatment-Resistant Depression—Advantage Ketamine?

SJ Mathew, MK Jha, A Anand - JAMA psychiatry, 2023 - jamanetwork.com
This Viewpoint examines key issues stemming from severalrecentreportsofelectroconvulsivether…
(ECT) vs ketamine infusion for improving depressive symptoms in treatment-resistant …

Ketamine and psychotherapy for the treatment of psychiatric disorders: systematic review

BM Kew, RJ Porter, KM Douglas, P Glue… - BJPsych Open, 2023 - cambridge.org
Background Ketamine is an effective short-term treatment for a range of psychiatric
disorders. A key question is whether the addition of psychotherapy to ketamine treatment …